TriLeaf BioPharma Limited (TriLeaf Bio-B) resubmitted the Securities Change Monthly Report as of September 30, 2024 to the Hong Kong Exchanges and Clearing Limited on November 6, 2024. The report shows that the company's statutory/registered share capital remains unchanged at 2,000,000,000 ordinary shares, with a par value of $0.0001 per share, totaling $200,000. The issued shares (excluding treasury shares) increased from 1,297,048,929 shares last month to 1,297,054,929 shares, an increase of 6,000 shares. This increase originated from the exercise of share options under the stock options plan before the initial public offering. The company confirms that all securities issuance or sale of treasury shares have obtained formal approval from the board of directors and comply with all applicable listing rules, laws, and other regulatory requirements.

TriLeaf BioPharma Limited (TriLeaf Bio-B) resubmitted the Securities Change Monthly Report as of September 30, 2024 to the Hong Kong Exchanges and Clearing Limited on November 6, 2024. The report shows that the company's statutory/registered share capital remains unchanged at 2,000,000,000 ordinary shares, with a par value of $0.0001 per share, totaling $200,000. The issued shares (excluding treasury shares) increased from 1,297,048,929 shares last month to 1,297,054,929 shares, an increase of 6,000 shares. This increase originated from the exercise of share options under the stock options plan before the initial public offering. The company confirms that all securities issuance or sale of treasury shares have obtained formal approval from the board of directors and comply with all applicable listing rules, laws, and other regulatory requirements.